|4/AFeb 5, 4:30 PM ET

Bharucha David 4/A

4/A · Milestone Pharmaceuticals Inc. · Filed Feb 5, 2026

Research Summary

AI-generated summary of this filing

Updated

Milestone (MIST) CMO David Bharucha Receives 204,000-Share Award

What Happened
David Bharucha, Chief Medical Officer of Milestone Pharmaceuticals (MIST), was granted a derivative award covering 204,000 shares on February 2, 2026. The filing shows the acquisition price as $0.00 and is an amended Form 4 correcting prior exercise-price information. This was a grant (not an open-market purchase or sale) and the shares are subject to vesting.

Key Details

  • Transaction date: February 2, 2026 (reported on amended Form 4 filed Feb 5, 2026).
  • Transaction type: Derivative award/grant for 204,000 shares; reported price $0.00.
  • Shares owned after transaction: Not specified in this filing.
  • Footnotes:
    • F1: The exercise price on the initial filings was incorrectly stated (this filing amends that).
    • F2: Vesting schedule — 1/4 of the option vests on Feb 2, 2027, then 1/36th of the remaining shares vests each month thereafter, contingent on continued service.
  • Filing status: Amended Form 4 (correction to earlier filing).

Context
This is a derivative grant subject to time-based vesting; it does not represent an immediate sale or open-market purchase. For retail investors, such grants are common for employee compensation and do not by themselves indicate buying or selling conviction. The amended filing corrects exercise-price information and clarifies the vesting schedule.

Insider Transaction Report

Form 4/AAmended
Period: 2026-02-02
Bharucha David
Chief Medical Officer
Transactions
  • Award

    Employee Stock Option (right to buy)

    [F1][F2]
    2026-02-02+204,000204,000 total
    Exercise: $1.96Exp: 2036-02-02Common Shares (204,000 underlying)
Footnotes (2)
  • [F1]The exercise price on the initial filings was incorrectly stated.
  • [F2]One-fourth (1/4th) of the shares subject to the option vest on February 2, 2027, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
Signature
/s/ Joseph Oliveto, Attorney-in-Fact|2026-02-05

Documents

1 file
  • 4
    form4a-02052026_040214.xml